Labcorp launches first-of-its-kind immunoassay to accelerate path to diagnosis of alzheimer's disease

Labcorp's ptau-217/beta amyloid 42 ratio blood test meets the performance criteria to confirm amyloid pathology consistent with alzheimer's disease burlington, n.c. , april 2, 2025 /prnewswire/ -- labcorp (nyse: lh), a global leader of innovative and comprehensive laboratory services, announced today the nationwide launch of its ptau-217/beta amyloid 42 ratio, a powerful new blood-based biomarker test to aid in the diagnosis of alzheimer's disease.
LH Ratings Summary
LH Quant Ranking